Construction and validation of an ACTA2-based prognostic scoring model for colorectal adenocarcinoma

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-09-17 DOI:10.1016/j.tranon.2025.102530

Xiao Che , Wenwei Huang , Yao Ying , Yuzhen Zhu , Yang Yang , Ke Mo , Xueqiong Han , Chunhui Cui , Lu Zhou

引用次数: 0

Abstract

This study aimed to construct and validate a clinical scoring model for colorectal adenocarcinoma (COAD) based on ACTA2 to identify novel biomarkers. COAD-related data were obtained from the TCGA database, and the expression of ACTA2 was verified by in vitro experiments. WGCNA analysis was used to explore the biological processes associated with ACTA2. The results showed that ACTA2 was downregulated in COAD tissues, but its high expression was significantly associated with poor prognosis in patients. ACTA2 was closely related to immune cell infiltration, immune checkpoint genes, and tertiary lymphoid structure marker genes. In addition, there was a negative correlation between the methylation level and transcriptional level of ACTA2. The ACTA2-based clinical scoring model constructed in this study may serve as a novel biomarker for COAD, providing new insights for improving patient prognosis.

Abstract Image

查看原文本刊更多论文

基于acta2的结直肠腺癌预后评分模型的构建与验证

本研究旨在构建并验证基于ACTA2的结直肠腺癌（COAD）临床评分模型，以鉴定新的生物标志物。coad相关数据来源于TCGA数据库，ACTA2的表达通过体外实验进行验证。采用WGCNA分析探讨与ACTA2相关的生物学过程。结果显示，ACTA2在COAD组织中表达下调，但其高表达与患者预后不良显著相关。ACTA2与免疫细胞浸润、免疫检查点基因、三级淋巴结构标记基因密切相关。此外，ACTA2的甲基化水平与转录水平呈负相关。本研究构建的基于acta2的临床评分模型可作为一种新的COAD生物标志物，为改善患者预后提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.